26.01.2021 • NewsCorbion

Corbion Expands North American Lactic Acid

Dutch lactic acid specialist Corbion said it plans to increase its North American capacity by about 40% to meet growing demand for natural ingredients in multiple industries and reinforce its position as a leading worldwide supplier of lactic acid and derivatives.

The expansion will take place at the company’s US plant in Blair, Nebraska, USA. Corbion, which also produces lactic acid in the Netherlands, Brazil, Spain and Thailand, did not disclose capacity figures or a start-up date for the expanded capacity. In early 2020 it announced plans to expand its offering in Asia with a new plant at an existing site in Rayong Province, Thailand.

Corbion said it aims to achieve the US expansion at in the most sustainable way possible. Without giving details, it said it will employ technology designed to enable a significant boost in efficiency while avoiding an increase in emissions, thus demonstrating that production growth can be decoupled from CO2 output.

The use of lactic acid and its derivatives as ingredients in foods and beverages for safe preservation, and in home and personal care products for effective but gentle disinfection and hygiene, has increased steadily in the Americas over the past five years, the company said.  

Author: Dede Williams, Freelance Journalist

 

Dutch lactic acid specialist Corbion plans to increase North American output by...
Dutch lactic acid specialist Corbion plans to increase North American output by 40% to meet growing demand for natural ingredients and reinforce its position as a leading supplier worldwide. Capability will be added at Blair, Nebraska. No start-up date has been given. (c) Corbion

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read